Fiche centre
Guangzhou First People's Hospital
Guangzhou — China
Essais liés5clinical trials
VilleGuangzhoulocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06531824
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BI 690517 | Maladie rénale chronique | Phase 3 | NCT06531824 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | ACTIVE_NOT_RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT05810038 | A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects. | COMPLETED |
| PF-06821497 | Cancer | Phase 3 | NCT06629779 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | RECRUITING |
| Galcanezumab | Migraine | Phase 3 | NCT03963232 | PERSIST — A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT06616194 | A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine | ACTIVE_NOT_RECRUITING |